Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis

Lingshu Zhang1,2,3, Pingfang Song1, Xiaowei Zhang3, Christina Metea4, Matthew Schleisman4, Lisa Karstens5, Eric Leung5, Jun Zhang6, Qiang Xu1,7, Yi Liu2, Mark Asquith1 and Cong-Qiu Chu1,3*

1 Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, United States, 2 Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China, 3 Section of Rheumatology, VA Portland Health Care System, Portland, OR, United States, 4 Casey Eye Institute, Oregon Health & Science University, Portland, OR, United States, 5 Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR, United States, 6 Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 7 Department of Rheumatology, The First Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China

Acarose is an anti-diabetic drug and exhibits anti-arthritic effects. We hypothesized that acarbose influences the gut microbiota to affect the course of arthritis and tested this hypothesis in a collagen-induced arthritis (CIA) murine model. Acarbose in drinking water was administered via gastric gavage started prior to or at the time of CIA induction. Gut microbiota were evaluated with 16S rRNA gene sequencing from fecal pellets collected prior to arthritis induction, during onset of arthritis, and after treatment. Immune response was evaluated by measuring changes in T helper-17 (Th17) and T regulatory (Treg) cells in the spleen and intestine, as well as serum cytokine levels. Before induction of CIA, acarbose significantly reduced the incidence of arthritis and attenuated clinical severity of arthritis. The frequency of Th17 cells was significantly decreased in the intestinal lamina propria in acarbose treated mice. Mice that were treated with acarbose showed significantly increased CD4+CD25+Foxp3+ Treg cells with elevation of Helios and CCR6. A remarkable alteration in microbial community was observed in acarbose treated mice. Bacterial diversity and richness in mice with arthritis were significantly lower than those in acarbose treated groups. The frequency of Firmicutes was significantly reduced after arthritis onset but was restored after treatment with acarbose. The frequency of Lactobacillus, Anaeroplasma, Adlercreutzia, RF39 and Corynebacterium was significantly higher in control groups than in acarbose treated, while Oscillospira, Desulfovibrio and Ruminococcus enriched in acarbose treated group. Miglitol, another α-glucosidase inhibitor showed a similar but less potent anti-arthritic effect to that of acarbose. These data demonstrate that acarbose alleviated CIA through regulation of Th17/Treg cells in the intestinal mucosal immunity, which may have resulted from the impact of acarbose on gut microbial community. Inexpensive antidiabetic drugs with an excellent safety profile are potentially useful for managing rheumatoid arthritis.

Keywords: acarbose, arthritis (including rheumatoid arthritis), microbiome, Th17, Treg cells
INTRODUCTION

Acarbose is the prototype of alpha-glucosidase inhibitors and a widely used anti-diabetic drug. Acarbose is a pseudo-carbohydrate that competitively inhibits α-glucosidase, which is located in the brush border of the small intestine, leading to the delay of intestinal absorption of carbohydrates and therefore slows down the absorption of sugars (Bischoff, 1994), and reduced postprandial increases in blood glucose. Acarbose is primarily prescribed to patients with type 2 diabetes as monotherapy or as add-on to other antidiabetic drug treatment (Joshi et al., 2015), especially in those with poorly controlled blood glucose by other antidiabetic drugs. Additional benefits have been noticed in diabetic patients treated with acarbose such as reduced risk for myocardial infarction and improved lipid profile and reduced levels of inflammatory cytokines in peripheral blood (Hanefeld and Schaper, 2008; Joshi et al., 2015; Su et al., 2015).

Recently, it has been observed that diabetic patients treated with acarbose have a decreased risk for developing rheumatoid arthritis (RA) (Chen et al., 2015) suggesting an anti-inflammatory effect by acarbose. The anti-inflammatory effect of acarbose has been experimentally proven in two mouse models of inflammation, namely collagen-induced arthritis (CIA) and a psoriasis model (Chen et al., 2015; Chen et al., 2016). In the two models of inflammatory diseases, daily administration of acarbose attenuated the diseases severity.

RA is a chronic autoimmune disease involving inflammation of the synovial joints that leads to cartilage degradation, bone erosion, and joint destruction. The cause of RA remains obscure, but interplay of genetic and environmental risk factors are thought to be responsible. Recently, dysbiosis of the gut microbiota has been considered as a contributor to RA etiopathogenesis (Scher and Abramson, 2011; Phillips, 2015; Rogers, 2015). Interestingly, the microbiota dysbiosis in RA can be partially normalized by disease-modifying anti-rheumatic drugs (DMARDs) in those RA patients achieved remission of low disease activity (Zhang et al., 2015) indicating that gut microflora biosis is associated with RA disease status. Patients with diabetes treated with acarbose have increased gut Bifidobacterium longum and Enterococcus facalis (Su et al., 2015). Moreover, mice fed with acarbose have increased lifespan (Harrison et al., 2014; Harrison et al., 2019). The enhanced longevity in acarbose treated mice is associated with changes in the gut microbiome (Smith et al., 2019). Given the linkage of decreased risk of developing RA in diabetic patients treated with acarbose, anti-inflammatory effect of acarbose in CIA, alteration of gut microbiome in mice treated with food supplement with acarbose, we hypothesized that acarbose exerts anti-inflammatory effects via alteration of the gut microbiota, and tested this idea in CIA by analyzing changes of bacterial composition before and after treatment with acarbose. Since CIA is known to be T helper 17 (Th17) cell dependent and displays T regulatory (Treg) cell functional defect (Chu et al., 2007; Morita et al., 2011), we focused on the immune changes of Th17 and Treg cells in the intestine and correlating them with changes of gut microbiota after acarbose treatment.

MATERIALS AND METHODS

Mice and Induction of CIA and Clinical Assessment of Arthritis

Male DBA/1 mice (8–10 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME). All mice were maintained in a specific, pathogen-free facility and housed in microisolator cages containing sterilized food, bedding and water. All animal experiments were performed under protocols approved by Institutional Animal Care and Use Committee of VA Portland Health Care System. Arthritis was induced by immunization with intradermal injection of 100 μg of chicken type II collagen (CII) (Chondrex, Inc., Seattle) emulsified 1:1 with complete Freund’s adjuvant (CFA) and boosted on day 35 with an intraperitoneal injection of 25 μg of bacterial lipopolysaccharide (LPS). All mice were examined daily for the initial visual appearance of arthritis. Severity of arthritis was classified using a scoring system as described (Chu et al., 2007). Score 0: No evidence of erythema and swelling; Score 1: Erythema and mild swelling confined to the tarsals or ankle joint; Score 2: Erythema and mild swelling extending from the ankle to the tarsals; Score 3: Erythema and moderate swelling extending from the ankle to metatarsal joints; Score 4: Erythema and severe swelling encompassing the ankle, foot and digits, or ankylosis of the limb. The maximum score of each mouse is 16.

Treatment Protocols

To investigate whether acarbose prevents arthritis and suppresses joint destruction in vivo, we developed two experimental protocols based on published data (Chen et al., 2015; Chen et al., 2016). In the first protocol (Figure 1A), mice were gavaged with 300 μl of acarbose 500 mg/kg, miglitol 500 mg/kg or drinking water daily starting at 7 days prior to induction of arthritis (before induction). In another protocol (Figure 1B), mice were gavaged with 300 μl of acarbose 500 mg/kg, miglitol 500 mg/kg or drinking water every day starting on the day of arthritis induction (at induction). All mice were euthanized on day 55 after arthritis induction.

Cell Isolation and Purification of Spleen and Intestinal Lamina Propria T Cells

Spleen was removed and cells were isolated via single cell suspension by mechanical disruption through a 100 μm cell strainer. Lysis of erythrocytes was performed for spleens. To isolate cecum and colon intestinal lamina propria (LP), cecum and colons were removed, opened longitudinally, contents were flushed with ice-cold PBS containing 0.1% bovine serum albumin (BSA). Intestines were cut into 3 mm in length and incubated for 30 min at 37°C with RPMI 1640 containing 3% fetal bovine serum (FCS), 5 mM EDTA, 10 mM HEPES, 10% FCS, 50 U/ml penicillin, and 100 μg/ml streptomycin (Gibco, USA) with 1 mM dithiothreitol (DTT, Fisher Scientific, Pittsburgh) with gentle shaking at 37°C for 30 min to remove the epithelium and intraepithelial lymphocytes. Tissues were washed with PBS containing 0.1% BSA twice, then followed by incubation with 0.2 mg/ml collagenase II (Sigma) and 0.1 mg/ml DNase I (Roche).
with stirring at 37°C for 45 min. Cells were then filtered through a 40 μm cell strainer and harvested at the interface of a 40%/70% Percoll (GE Healthcare) gradient, then washed in PBS containing 0.1% BSA for assays.

**Flow Cytometry**

Intracellular staining was performed as follows. Cells were stimulated with phorbol myristate acetate (50 ng/ml, Calbiochem) plus ionomycin (500 ng/ml, Merck & Company) for 4 h, with Golgi Plug (BD Biosciences). After cell surface staining with antibodies to CD4, CD25 and CCR6 (BioLegend), cells were fixed and permeabilized Fix/Perm buffer (eBioscience) overnight at 4°C. Antibodies to Helios, IL-17A and Foxp3 (eBioscience) were added and incubated for 30 min at 4°C. Cells were acquired with a BD LSRII and data were analyzed using FlowJo (V10, USA) software.

**Histopathology of Arthritis**

Mouse joint tissues were removed, fixed in 10% formalin, decalcified, embedded in paraffin and sectioned at 6 μm. Sections were stained with hematoxylin and eosin, Safranin-O and toluidine blue to detect synovitis, pannus formation, and marginal erosion of the joint and articular architectural changes.

**Anti-CII Antibody Quantification**

Mouse serum samples were collected at the end of the experiment. Antibodies of different isotypes to chicken and murine CII (Chondrex, Seattle, WA) were determined by enzyme linked immunosorbent assay (ELISA), as previously described (Chu et al., 2003). Microtitre plates were coated with 5 μg/well of native chicken or murine CII in potassium phosphate coating buffer (pH 7.4) overnight at 4°C, followed by blocking with an overnight incubation at 4°C with blocking buffer (2% BSA in PBS). Serum samples diluted at 1:4,000 in PBS containing 0.05% Tween 20 and 0.5% BSA were incubated 1 h at room temperature. Goat anti-mouse IgG, IgG1, IgG2a and IgG2b conjugated to alkaline phosphatase (Jackson ImmunoResearch Laboratiorie) diluted at 1:5,000 were incubated for 30 min at room temperature to detect anti-CII or anti-mouse antibody isotypes and IgG subclasses. The optical density at 450 nm was read with a Molecular Devices plate reader (Molecular Devices, Menlo Park, CA). Antibody levels were expressed as arbitrary units with reference to a standard serum.

**Multiplex Cytokine Assay**

Serum levels of various cytokines (IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, IFN-γ, and tumor necrosis factor (TNF)-α) were determined using the LEGENDplex™ Mouse Th Cytokine Panel (13-plex) array (Biolegend) according to the manufacturer’s protocol. The data were collected on a LSR II flow cytometer and analyzed using the LEGENDplex™ software version 7.0 (Biolegend).

**Fecal Pellet Collection**

Fecal pellets for microbial community analysis were collected before arthritis induction (day −7), at arthritis induction (day 0), onset of arthritis (day 37), and at the termination of the experiment (day 55). Fecal samples and cecal contents from mice housed under specific pathogen-free conditions were harvested under sterile conditions in a 1.5 ml Biopure tube (Eppendorf) and immediately snap frozen and stored at −80°C until processing for DNA isolation.
16S rRNA Gene Sequencing
DNA was isolated from fecal pellets and cecal contents using PowerSoil DNA Isolation Kit (MoBio Laboratories Inc., Carlsbad, CA) according to the manufacturer’s instructions. DNA concentration was confirmed by Nanodrop spectrophotometer prior to normalization to ~20 ng/µl. Quantitative real-time PCR (qRT-PCR) amplification was performed using a set of primers targeting the V4 hypervariable regions of the 16S rRNA gene using the 515F–806R primers and sequenced on the Illumina MiSeq platform (Caporaso et al., 2012). The primers used were as follows: FWD : GTGCCAGCMGCGCCGCTAAT (original, rev-barcoded: 515F-806R). Each PCR amplification reaction contained 1 µl of DNA extract, 0.2 mM dNTPs, 0.2 mM forward primer, 1 µl reverse primers, 48 µl of master mix containing 1× colorless reaction buffer, 1.5 mM MgCl₂ and 1.25 U of polymerase enzyme. The reaction volumes were placed in a thermocycler and run through the following conditions: 94°C for 3 min (initial denaturation), followed by 35 cycles of 94°C for 45 s (denaturation), 55°C for 40 s (annealing) and 72°C for 1.5 min (extension) and ending with a last step of 72°C for 10 min.

The final steps of library preparation were performed with the Illumina Miseq V2 kit. The DNA library was diluted to 4 nM and denatured with NaOH for 5 min. The library was then diluted to a final concentration of 6.6 pM in hybridization buffer HT1 (Illumina), spiked with 5% PhiX control heated to 96°C for 2 min prior to incubation for 5 min on ice and then loaded onto the MiSeq cartridge. A 500 cycle MiSeq Reagent Kit v2 was used and run on the Illumina Miseq instrument.

16S rRNA Gene Sequencing Analysis and Bioinformatics
Primers and sequence adapters were removed with the Illumina MiSeq Reporter (version 2.5) and further processed using the Quantitative Insights Into Microbial Ecology (QIIME) pipeline version 1.9.0 (Caporaso et al., 2010), the Vegan package in R (Dixon, 2003) and Linear discriminant analysis (LDA) effect size (LEfSe) (Segata et al., 2011). To adjust for multiple comparisons the Benjamini–Hochberg method was used (Benjamini and Hochberg, 1995). Taxonomy was assigned with the BLAST consensus method of QIIME, using the most recent version of the GreenGenes database (v.13.8) (DeSantis et al., 2006). Chimeric sequences were detected and removed using the blast calculated identify_chimeric_seqs.py. Operational taxonomic units (OTU) were picked using UCLUST at 97% sequence identity. Rarefaction was performed to subsample each sample to 17,000 reads prior to comparing the abundance of OTU across samples. We assessed α-diversity with observed OTU count and the Chao1 Estimator for microbial richness. Between group β-diversity was evaluated with unweighted UniFrac distances and principal coordinate analysis in QIIME and statistically evaluated using PERMANOVA. LEfSe analysis was implemented in Galaxy (version1.0) and performed using standard parameters (p < 0.05 and LDA score 2.0).

Statistical Analysis
Nonparametric data were compared using Mann–Whitney U test, and parametric data were compared using Student’s t-test. All statistical analyses were calculated in Prism (GraphPad Prism 5). Differences were considered to be statistically significant when P < 0.05.

RESULTS
Acarbose Suppressed CIA
Acarbose dissolved in drinking water was administered via gastric gavage at 500 mg/kg daily. This dose was chosen based on previously published protocol in which 500 mg/kg was effective while 100 mg/kg did not have effect on arthritis or psoriasis models (Chen et al., 2015; Chen et al., 2016). Miglitol was included as a control drug to acarbose. Miglitol is a second generation of α-glucosidase inhibitor (Sels et al., 1999). While greater than 98% of orally dosed acarbose is not absorbed (Dash et al., 2018), miglitol is completely absorbed by the small intestine (Sels et al., 1999; Dash et al., 2018) and therefore, an appropriate control for gut activity of acarbose. Oral administration of acarbose significantly suppressed CIA when given prior to or at the time of arthritis induction and reduced incidence of CIA when given prior to induction of arthritis (Figure 1). The arthritis inhibition effect of acarbose, however, is less potent if given at the time of arthritis induction. The arthritis inhibition effect was demonstrated by histological analysis. In the group of animals treated by acarbose 7 days prior to arthritis induction, 37% of arthritic joints were identified as mild, whereas only 14% of arthritic joints were mild in the drinking water treated group (Table 1). In contrast, in the animals treated at induction, 52% of arthritic joints were identified as severe with joint structure destruction in drinking water treated animals, compared with only 16% of the joints belonged to the severe category in acarbose group (Figure 1 and Table 1). Miglitol also had arthritis inhibiting effects but much less potent than acarbose (Figure 1 and Table 1).

| Treatment | Number of joints assessed | Severity (%) |
|-----------|--------------------------|--------------|
|           | MILD | MODERATE | SEVERE |
| Water     | 35   | 5 (14) | 12 (34) | 18 (52) |
| Miglitol  | 36   | 11 (31)# | 16 (44)# | 9 (25)** |
| Acarbose  | 38   | 14 (37)*** | 18 (47)# | 6 (16)* |

*p = 0.001 (Acarbose vs control).
**p = 0.02 (Miglitol vs control).
***p = 0.03 (Acarbose vs control).
#Not statistically significant.

The severity of arthritis in each joint was classified as mild, moderate or severe based on the following criteria: mild, minimal synovitis, cartilage loss and bone erosions limited to discrete foci; moderate, synovitis and erosions present but normal joint architecture intact; severe, synovitis, extensive erosions, and joint architecture disrupted (as shown in Figure 1C, Williams et al., 1992; Chu et al., 2003).
Modulation of Immune Response by Acarbose

We next sought to identify if α-glucosidase inhibitors modulates the antigen-specific systemic immune response, thereby resulting in protection against CIA. Immunized DBA/1 mice are known to cause elevation of anti-CII antibodies and these antibodies are pathogenic. We measured CII-specific anti-chicken CII and murine CII autoantibody production in serum. Mice treated with acarbose started before arthritis induction showed a significant reduction in levels of anti-chicken CII total IgG, IgG1 and IgG2b antibodies compared to control mice (Figure 2). No significant changes were observed in the group of mice treated starting at arthritis induction (Figure 2). We did not find any difference between groups in CII type II anti-murine autoantibodies. We measured levels of pro- and anti-inflammatory cytokines. Mice treated with acarbose significantly reduced IL-9 (P < 0.05) and IL-6 (P < 0.001) while miglitol reduced IL-9 (P < 0.05) compared with mice gavaged with water alone in the protocol of treatment starting before arthritis induction. Mice treated with acarbose also showed a significantly decreased level of IL-6 in mice treated at arthritis induction (P < 0.05). None of the α-glucosidase inhibitors treated mice in both protocols showed any significant changes in cytokines levels of IL-10 and interferon (IFN)-γ compared with water-treated controls (Figure 2). For the remaining analyzed serum factors related to T-cell activation status (IL-4, IL-5, IL-13, IL-17A, IL-17F, IL-21, IL-22, IL-23 and TNF), no obvious differences were detected or a comparative analysis was not feasible because of serum levels being predominantly or completely below the detection limit of the applied assays in either mouse group (data not shown).

Modulation of α-Glucosidase Inhibitor Treatment in Th17 and T Regulatory (Treg) Cells

To confirm that the treatment with α-glucosidase inhibitors modulate innate and intestinal immune system, we compared spleen and large intestine LP lymphocytes by flow cytometry. We focused on Th17 and Treg cells since Th17 and Treg imbalance is involved in the pathogenesis of CD4+ T cells in DBA/1 mice during CIA (Chu et al., 2007; Morita et al., 2011). There was no difference of Th17 cells was detected in the spleen in either treatment protocols, or in gut LP in mice treated at arthritis induction groups. On the other hand, the frequency of Th17 cells was significantly decreased in the intestinal sites in both acarbose and miglitol when treatment started prior to arthritis induction (Figure 3). To examine the anti-inflammatory response in the mice, we chose two well-characterized markers, Helios+ and CCR6+ of Treg cells which have been previously demonstrated to provide robust results and reproducible result in Treg cells. Mice treated with acarbose prior to arthritis induction had significantly increased CD4+CD25+Foxp3+ Treg cells as well as elevation of Helios and CCR6 as demonstrated in both percentage and absolute Treg cell numbers (Figure 3 and

![FIGURE 2](image-url) | Anti-collagen type II autoantibody and cytokine production. Mice were treated with acarbose, miglitol or water as in Figure 1 (Before Induction or At Induction). Serum levels of IgG, IgG1, IgG2a and IgG2b anti-collagen type II were determined by specific enzyme-linked immunosorbent assay (A) and concentrations of cytokines were determined by the LEGENDplex mouse Th cytokine panel (13-plex) array (B). Data were expressed as mean ± SEM. These results consist of the average of two independent experiments, five mice per group. *p < 0.05, **p < 0.01, vs control group.
FIGURE 3 | α-glucosidase inhibitor treatment on the mouse spleen and intestinal immune systems. Mice were treated with acarbose, miglitol or water as in Figure 1 (Before Induction or At Induction). The number of Th17 and Treg cells in mouse spleen and gut lamina propria was analyzed using flow cytometry. (A) Th17 cells: Lymphocytes were stimulated and stained with CD4 and IL-17A antibodies. Each dot plot shows data from one representative mouse of each group. The number in the right upper quadrant indicates the percentage of CD4+IL-17+ lymphocytes. Bar graphs represent the data expressed as mean ± SEM. (B-E) Treg cells: Percentage of Treg cells (CD4+CD25+Foxp3+) (B), Helios+ Treg cells (CD4+CD25+Foxp3+Helios+) (C) and CCR6+ Treg cells (CD4+CD25+Foxp3+CCR6+) (D) was quantified by flow cytometry. Each dot plot shows data from one representative mouse of each group. (E) Bar graphs represent the data of total Treg, Helios+ Treg and CCR6+ Treg cells expressed as mean ± SEM. These results were average of two independent experiments, 7-10 mice per group. *p < 0.05, **p < 0.01, vs control group.
TABLE 2 | Acarbose induced increase of Treg cells in lamina propria1.

|                      | Spleen          | Lamina Propria |
|----------------------|-----------------|---------------|
|                      | Treg           | p*            | CCR6*Treg | p    | Helios*Treg | p    |
| Before Induction     |                 |               |           |      |             |      |
| Water                | 514 ± 64        | 171 ± 91      | 355 ± 111 |      |             |      |
| Miglitol             | 525 ± 51        | 0.67          | 138 ± 22  | 0.31 | 385 ± 30    | 0.44 |
| Acarbose             | 498 ± 71        | 0.62          | 171 ± 107 | 1.00 | 349 ± 77    | 0.20 |
|                      |                 |               |           |      |             |      |
| At Induction         |                 |               |           |      |             |      |
| Water                | 496 ± 94        | 168 ± 91      | 367 ± 84  |      |             |      |
| Miglitol             | 502 ± 59        | 0.88          | 163 ± 54  | 0.87 | 396 ± 72    | 0.81 |
| Acarbose             | 457 ± 76        | 0.35          | 159 ± 70  | 0.81 | 355 ± 70    | 0.42 |

1Absolute Treg cell numbers were derived from % of Foxp3+ or Foxp3+/CCR6+ or Foxp3+/Helios+ CD4+/CD25+ T cells out of a total of 50,000 cells acquired on flow cytometry. Pooled data of two experiments with n = 7–10 mice in each group. The values are mean ± SD.

*p values are comparison of miglitol or acarbose treated group with water treated.

Table 2). Treatment with miglitol also observed increased percentage of CD4+CD25+Foxp3+ Tregs (P <0.01) and CCR6+ (P < 0.05) in the mucosal sites (Figure 3), but the increased absolute number of Treg cells did not reach statistical significance (Table 2). Whereas, neither CD4+CD25+Foxp3+Helios+ nor CCR6+ response to α-glucosidase inhibitors was observed in the groups when treatment started at arthritis induction (Figures 3C, D). This confirmed α-glucosidase inhibitors have a prophylactic effect on lymphocytes residing in the gut lamina propria. α-glucosidase inhibitors suppressed induction of Th17 cells and with a trend towards an increase of Treg cells. As α-glucosidase inhibitors modulated Th17/Treg subsets, we addressed the question of whether α-glucosidase inhibitors could affect the gut microbiota at the site which may further adjust the differentiation of Th cells.

Alteration in Microbial Community and Function by α-Glucosidase Inhibitors

Fecal pellets were collected for analysis by V4 rRNA sequencing before treatment (on day −7 or 0), during onset of arthritis (on day 37) and at the end of treatment (on day 55). Cecal contents were collected at the end of the experiments (on day 55). Reads were clustered into 1,010 ± 228 OTUs at 97% identity. We then examined whether fecal microbiota richness and diversity, as estimated by the number of observed OTUs and Chao1 estimators, were changed by α-glucosidase inhibitors treatment in different treatment arms (Figure 4A). Rarefaction curves plateaued after 15,000 reads per sample, approximating a saturation phase. The variability of OTUs estimated in controls was lower compared to the acarbose groups in animals treated before or at the time of arthritis induction. As shown by the Chao1 estimator, bacterial diversity and richness in CIA control mice with arthritis was significantly lower than in acarbose treatment groups (P < 0.05). All measures indicate a much higher biodiversity within the acarbose treatment than in water control samples (Figure 4A).

We next sought to evaluate overall differences in beta-diversity between the microbial communities. We applied the unweighted UniFrac metric (Lozupone and Knight, 2005) to calculate pairwise distances between samples, which takes into account phylogenetic distances among microbes and their presence or absence. As shown from principal coordinate analysis (PCoA) plot (Figure 4B), at the end time point a clear separation between the acarbose and the control group was observed in both before and at arthritis induction treatment groups in the colon and cecum (P <0.05, permutation test with pseudo F-ratio). Within the miglitol microbial community cluster, there appears to be clear difference in treatment groups (P < 0.05), but not observed in groups treated before arthritis induction compared with control. Notably in the cecum, we also found significant differences between groups in both before and at arthritis induction treatment groups (P <0.05) (Figure 4B). This evidence suggested that the overall composition of the microbial community was significantly changed in the α-glucosidase inhibitor treatment groups.

We hypothesized that there would be compositional changes in the intestinal microbiota between treatment groups. At the phylum level, Firmicutes and Bacteroidetes were the two largest phyla represented in each group (Figure 4C). In the prophylactic groups, Firmicutes and Bacteroidetes exhibited large shifts during treatment. Firmicutes were significantly reduced after arthritis onset and the ratio of Firmicutes increased in the α-glucosidase inhibitors treatment groups. In the group of acarbose treatment before arthritis induction, Firmicutes was higher before immunization (68.63%), lower at arthritis onset (38.97%) and restored after treatment (66.75%). The microbiota composition was similar in the miglitol treatment group. The proportional abundance of Firmicutes was higher before immunization (76.82%) and decreased with arthritis onset (32.48%) and increased after treatment (67.60%). In contrast, Firmicutes dropped after immunization but was unable to be restored (52.71%) in controls. This trend was also detected in the treatment groups, at the end of the study α-glucosidase inhibitors restored Firmicutes which was significant (P <0.01).

To determine whether the intestinal microbiota contributes directly to arthritis progression, we generated a cladogram with LEfSe to detect bacterial taxa with significantly different abundances between groups (Segata et al., 2011). A comparison between the α-glucosidase inhibitor treatment and control groups.
FIGURE 4 | Continued

A

B

Key

Colon

Before Induction

At Induction

Cecum

Before Induction

At Induction

PERMANOVA values

Site

Acarbose vs control

Miglitol vs control

Table: PERMANOVA values

| Site          | Acarbose vs control | Miglitol vs control |
|---------------|---------------------|----------------------|
| Before Induction Colon | 1.616 0.025         | 1.323 0.126          |
| Before Induction Cecum | 1.674 0.007         | 1.348 0.077          |
| At Induction Colon | 3.9049 0.001        | 2.3179 0.004         |
| At Induction Cecum | 1.677 0.017         | 1.47 0.004           |

C

Phylum

Before Induction

At Induction

Genus

Before Induction

At Induction

Zhang et al. Acarbose Ameliorates Arthritis

Frontiers in Pharmacology | www.frontiersin.org February 2020 | Volume 10 | Article 1684
FIGURE 4 | Alteration in microbial community by α-glucosidase inhibitors. Mice were treated with acarbose, miglitol or water as in Figure 1 (Before Induction or At Induction). (A) Alpha diversity of intestinal microbiota as represented by number of observed OTUs and Chao1 estimator. (B) Principal coordinate analysis (PCoA) plots displaying Beta diversity of microbiota by treatment group using unweighted UniFrac distances. (C) The composition of gut microbiota in colon at the phylum (left) and genus (right) levels. Each phylum/genus is represented by different color and its proportion of relative abundance per sample. Genera were filtered for those with ≥0.1% of total abundance. If full identification was not possible, f_ or g_ alone was used for family or genus, respectively. (D) Cladogram representing the most differentially abundant taxa enriched in microbiota from α-glucosidase inhibitors and control mice generated from LEfSe analysis. The central point represents the root of the tree (Bacteria), and each ring represents the next lower taxonomic level (phylum through genus). The diameter of each circle represents the relative abundance of the taxon. (E) Relative abundance of Lactobacillus, Anaeroplasma, Adlercreutzia, RF39, Oscillospira, Ruminococcus and Desulfovibrio; asterisks indicate level of significance by Mann-Whitney U test. These results consist of the average of two independent experiments, 7–10 mice per group. Mean values ± SEM are plotted; *p < 0.05, **p < 0.01, ***p < 0.001.
showed that 42 OTUs were significantly different from acarbose group and 38 OTUs were in miglitol groups among samples of treatment arms at genus level (Figures 4C, D). In addition, in the groups which treatment started prior to arthritis induction, LEfSe identified 19 discriminative features from acarbose groups but 8 OTUs were significantly higher in the miglitol group. As shown above, to identify the effect of α-glucosidase inhibitors on gut bacteria, we found that genus *Lactobacillus, Anaeroplasma, Adlercreutzia*, and RF39 was significantly higher in control groups than the α-glucosidase inhibitors treated littermates, while *Oscilliospora, Desulfovibrio and Ruminococcus* were enriched in the α-glucosidase inhibitors treated littermates compared with the control groups in the treatment arm (Figure 4E). We did not notice any significant difference between acarbose when compared with miglitol. Thus, we identified microbes which were altered between α-glucosidase inhibitors groups and control in the development of arthritis, suggesting roles of α-glucosidase inhibitors in host metabolic development.

**DISCUSSION**

In this study, we have shown that administration of α-glucosidase inhibitors, especially acarbose before arthritis induction has a potent modulatory effect upon reversing joint inflammation both clinically and histologically in CIA, but the effect was much less significant when treatment started at the time of arthritis induction. These results are consistent with those by Chen and colleagues (Chen et al., 2015) in which acarbose gained both clinical and histological improvement of CIA. The notable immunological feature in CIA mice is the excessive production of autoantibodies against CII which may initiate arthritis. Our data suggest that high titers of anti-chicken CII antibodies like IgG, IgG1 and IgG2b production in control mice may contribute to the more severe disease. Furthermore, acarbose treated mice produced significantly lower levels of these antibodies, which may prevent the development of arthritis. Another critical feature of CIA is the over expression of pro-inflammatory cytokines that could contribute to inflammation, articular destruction, and the comorbidities associated with arthritis. There is evidence suggesting that IL-9 production in Th17 cells has been related to autoimmune disease including type 1 diabetes (Nowak and Noelle, 2010), asthma (Kearley et al., 2011), and experimental autoimmune encephalomyelitis (Li et al., 2010). Since IL-9 is a Th17-associated cytokine, a few studies evaluated the function of IL-9 in the pathogenesis of RA (Dantas et al., 2015). IL-9 has recently been found to be overexpressed in RA synovial tissues and correlated with the degree of histological organization of B and T cells in ectopic lymphoid structures (Ciccia et al., 2015). Also, IL-9 was related to the presence of RA-related autoantibodies (Hughes-Austin et al., 2013). Our findings suggest that IL-9 is overexpressed in CIA control mice compared to that in mice prophylactic treatment with acarbose. In addition, mice treated with miglitol resulted in significant decreased expression of IL-9, indicating α-glucosidase inhibitors regulating IL-9 development of CIA. Numerous studies suggest that IL-6 contributes to the pathophysiology of RA. An IL-6 inhibitor is a desirable therapeutic option in the treatment of RA (Emery et al., 2008). Both acarbose and miglitol have been reported to suppress IL-6 levels in obese subjects (Arakawa et al., 2008; Derosa et al., 2011). In our study, the concentration of IL-6 was significantly lower in acarbose treated animals, which is consistent with the previous report in CIA mice (Chen et al., 2015).

The imbalance between Th17 and Treg cells has been tightly related to the pathogenesis of RA (McInnes and Schett, 2011) and CIA (Chu et al., 2003; Chu et al., 2007; Annunziato et al., 2009; van den Berg and Miossec, 2009; Morita et al., 2011). In our study, we did not notice any differences of Th17/Treg cells in the spleen between groups regardless whether mice were treated before or at the time of arthritis induction. Notably, our data on α-glucosidase inhibitors suggest that most of its anti-inflammatory effect is due to inhibition of intestinal mucosal immunity. α-glucosidase inhibitors suppressed Th17 responses associated with a relative induction of a Treg subset response. The proportion of Th17 cells in the gut LP was significantly lower in the mice treated with acarbose and miglitol before arthritis induction than those treated with drinking water. This suggests that the consumption α-glucosidase inhibitors are not simply immunosuppressive but immunoregulatory because it also favored the anti-inflammatory effect of Treg cells. Recently, it has been demonstrated that Helios-enriched Treg might exert increased suppressive effects (Zabransky et al., 2012; Baine et al., 2013). In addition, Helios expression in CD4⁺ T cells correlated inversely with the serum C-reactive protein level in RA patients (Takatori et al., 2015). CCR6⁺ Treg cells preferentially migrated to the colon during inflammation (Kitamura et al., 2010). Prophylactic administration of acarbose not only increased CD4⁺CD25⁺Foxp₃⁺ T cells but also elevated Helios and CCR6 in the intestine. Prophylactic administration of miglitol also led to an increased number of CD4⁺CD25⁺Foxp₃⁺ T cells and elevated expression of CCR6.

Host-commensal interactions have increasingly been related to the induction of numerous autoimmune inflammatory diseases both in experimental animals and in humans including inflammatory bowel disease (Xavier and Podolsky, 2007), diabetes (Cani et al., 2008), multiple sclerosis (Jangi et al., 2016) and RA (Scher and Abramson, 2011). Previous work has emphasized the anti-inflammatory effect of short chain fatty acids (SCFA) in elevating chronic inflammatory disease, α-glucosidase inhibitors prevent the digestion of the carbohydrates and non-digestible carbohydrates generally provide the main sources of energy for the microbial organism that produce SCFA in the large intestine. Intake of acarbose and miglitol results in larger proportions of undigested carbohydrates reaching the ileum and colon ascends where they are digested by bacteria to form SCFA (Hanefeld and Schaper, 2008). It has been shown by several studies that SCFA are potent inducer of Treg cells and modulate cytokine production (Arpaia et al., 2013; Furusawa...
et al., 2013; Harrison et al., 2014; Kim et al., 2014). Considering acarbose is almost not absorbed from the gastrointestinal tract, whereas, miglitol is well absorbed with 100% systemic bioavailability, these two drugs may reestablish the Th17/Treg to a "normal" state in the gut via different mechanisms. Smith and colleagues observed that the commensal bacterial metabolites in the colon - SCFA, selectively expand the frequency and number of Treg cells in the large intestine mediated by the G-protein-coupled free fatty acid receptor 43 (GPR43) (Harrison et al., 2014). SCFA, particularly butyrate has been recognized to regulate inflammation and immune responses which upregulated the production of anti-inflammatory cytokines and reduce IL-6 levels, resulting in the induction of CD4+CD25+ Treg cells (Asarat et al., 2016). Scheppach and colleagues (Scheppach et al., 1988) reported an increase in both butyrate concentration and excretion with the treatment of acarbose. The non-absorbed acarbose reaches colon to provide extra carbohydrates for commensal bacteria to digest for more SCFA production. This may explain the more potent anti-inflammation effects of acarbose than miglitol.

We undertook studies to define the community structure of the fecal microbiome in CIA arthritic models using high-throughput 16S rRNA gene sequencing. We observed more richness within α-glucosidase inhibitors treated groups than the control littermates. At the phylum level, more specific alteration was observed, including decreases in the ratio of member of the Firmicutes to Bacteroidetes at arthritis onset which was restored after treatment while controls were unable to restore Firmicutes. Several intestinal species of Firmicutes produce SCFA butyrate, which is known to play a key role in providing major energy source for colonic intestinal epithelial cells maintaining integrity of the gut epithelium, inhibiting inflammatory response, helping regulating the production and development of Treg cells in the colon (Segain et al., 2000).

At genera level, five genera flourished after treatment with α-glucosidase inhibitor, including Oscillospira, Ruminococcus and Desulfovibrio, while the abundance of Lactobacillus, Anaeroplasmia, Adlercreutzia Ruminococcus and RF39 were increased in mice with arthritis. Several intestinal organisms identified in this study as being altered in animal models have been demonstrated to be associated with RA. Lactobacillus was over-represented in the fecal, dental, and salivary microbiota of patients with RA than the healthy controls, and its abundance was particularly pronounced in severe cases (Arpaia et al., 2013; Su et al., 2015; Breban et al., 2017). Also, Lactobacillus was significantly more abundant in CIA-susceptible mice prior to arthritis onset than in CIA-resistant mice (Jangi et al., 2016), although previous clinical study demonstrated enhanced abundance of Lactobacillus with acarbose treatment in prediabetic patients (Zhang et al., 2017). On the other hand, we observed the relative abundance of Oscillospira to be greatly enriched following α-glucosidase inhibitors. Oscillospira is an enigmatic bacterial genus that has never been cultured, but is recently detected by 16S rRNA gene sequencing. Some Oscillospira species are likely to be able to utilize host glycans and can probably produce the SCFA, butyrate (Gophna et al., 2017). Oscillospira has been reported to have negative association with inflammatory diseases and lower body mass index, and is positively associated with lean and healthy subjects (Tims et al., 2013; Escobar et al., 2014; Goodrich et al., 2014). Notably, Oscillospira is significantly reduced in patients with Crohn’s disease (Walters et al., 2014) and also reduced in pediatric nonalcoholic steatohepatitis, an inflammatory disease of the liver characterized by deposition of large amounts of fat in the liver (Gophna et al., 2017). These studies imply that Oscillospira helps in reducing arthritis. In addition, Ruminococcus have been reported to be capable of fermenting glucose, xylose and indigestible diet fiber and produce acetate via acetyl-CoA from pyruvate and Wood-Ljungdahl pathway (Crost et al., 2013). Ruminococcus bromii is suggested as a keystone species for the degradation of resistant starch in the human colon which fermented by intestinal microbiota to secrete SCFA. Scher and colleagues (Scher, 2016) showed a significant lower level in members of the bacterial genus Akkermansia, Ruminococcus, and Pseudobutyrylavibrio in fecal samples from patients with psoriatic arthritis. Also, we found the abundance of genus Desulfovibrio, a gram-negative, aerotolerant, non-spore former was at a higher level following α-glucosidase inhibitors than their counterparts. Desulfovibrio species work synergistically with Prevotella species to degrade mucin (Arunugam et al., 2011). In addition, Desulfovibrio, Prevotella, and Oscillibacter can utilize microbial exopolysaccharides synthesized by Bifidobacterium to produce SCFA in the human intestine (Salazar et al., 2008).

Our study has limitations. Our results showed that dysbiosis of gut microflora composition during the course of CIA and the homeostasis was restored by acarbose treatment. These changes are associated with decreased Th17 cells and increased in Treg cells in the gut. However, our study did not provide direct evidence as to which bacterium directly contribute to the inflammation or anti-inflammatory effect, or contribute to maintain the balance between Th17 and Treg cells. Rather, our study shows an association between the reduced inflammation and restored gut microflora in acarbose treated mice. Further studies may need to focus on influence of acarbose on changes of commensal bacteria and their metabolites since commensal bacteria have been shown to selectively expand Treg cells (Smith et al., 2013).

In summary, changes in the gut microbiome and fermentation products in mice treated with acarbose have been associated with reduction of inflammation and with enhanced longevity (Smith et al., 2019) which may be due to decreased inflammation. The anti-arthritis effect of acarbose is best executed in prophylaxis of arthritis in the CIA model but less potent when treatment started at the time of arthritis induction. Considering the clinical usage of acarbose in management of RA, acarbose may have a place in preventing the development of RA in at-risk populations and in maintaining remission status of RA patients who have reached remission after treatment with DMARDs.
DATA AVAILABILITY STATEMENT
The raw datasets generated for this study can be found in the Bioproject with accession number: PRJNA589659.

ETHICS STATEMENT
The animal study was reviewed and approved by Institutional Animal Care and Use Committee of VA Portland Health Care System (protocol #: 3765-15).

AUTHOR CONTRIBUTIONS
LZ, YL, MA and C-QC conceived the project. LZ, PS, XZ, CM, MS, JZ and QX performed the experiments. LZ, LK, EL, MA and C-QC analyzed results. LZ, YL, MA and C-QC wrote the first draft. All authors revised the manuscript.

REFERENCES

Annunziato, F., Cosmi, L., Liotta, F., Maggi, E., and Romagnani, S. (2009). Type 17 T helper cells-origins, features and possible roles in rheumatic disease. *Nat. Rev. Rheumatol.* 5, 325–331. doi: 10.1038/nrrheum.2009.80

Arakawa, M., Ebato, C., Mita, T., Fujitani, Y., Shimizu, T., Watada, H., et al. (2008). Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. *Metabolism* 57, 1299–1306. doi: 10.1016/j.metabol.2008.04.027

Arpaia, N., Campbell, C., Fan, X., Diktyi, S., van der Weeken, J., de Roos, P., et al. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 504, 451–455. doi: 10.1038/nature12726

Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., et al. (2011). Enterotypes of the human gut microbiome. *Nature* 473, 174–180. doi: 10.1038/nature09944

Asarat, M., Apostolopolous, V., Vasiljevic, T., and Donkor, O. (2016). Short-chain fatty acids regulate cytokines and Th17/Treg cells in human peripheral blood mononuclear cells in vitro. *Immuno. Invest.* 45, 205–222. doi: 10.3109/08820393.2015.1125613

Baine, I., Basu, S., Ames, R., Sellers, R. S., and Macian, F. (2013). Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells. *J. Immunol.* 190, 1008–1016. doi: 10.4049/jimmunol.1200792

Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J. R. Stat. Soc. Ser. B (Methodological)* 57, 289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x

Bischoff, H. (1994). Pharmacology of alpha-glucosidase inhibition. *Eur. J. Clin. Invest.* 24 Suppl. 3, 5–78. doi: 10.1111/j.1365-2362.1994.tb02418.x

Breban, M., Tap, J., Leboime, A., Said-Nahal, R., Langella, P., Chiocchia, G., et al. (2013). Faecal microbiota study reveals specific dysbiosis in spondyloarthritics. *Ann. Rheum. Dis.* 76, 1644–1622. doi: 10.1136/annrheumdis-2016-211064

Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., et al. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* 57, 1470–1481. doi: 10.2337/db07-1403

Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., et al. (2010). QIIME allows analysis of high-throughput community sequencing data. *Nat. Methods* 7, 335–336. doi: 10.1038/nmeth.f.303

Crozat, A. G., Aubert, C., Marchal, F., Volan, D., Autelitano, L., Bouvrain, P., et al. (2013). Oral administration of acarbose ameliorates imiquimod-induced psoriasis-like dermatitis in a mouse model. *Int. Immunopharmacol.* 33, 70–82. doi: 10.1016/j.intimp.2016.02.001

Chen, H. H., Chao, Y. H., Chen, Y. M., Wu, C. L., Lai, K. L., et al. (2015). Acarbose decreases the rheumatoid arthritis risk of diabetic patients and attenuates the incidence and severity of collagen-induced arthritis in mice. *Sci. Rep.* 5, 18288. doi: 10.1038/srep18288

Chu, C. Q., Song, Z., Mayton, L., Wu, B., and Wooley, P. H. (2003). INFgamma deficient C57BL/6 (H-2b) mice develop collagen induced arthritis with predominant usage of T cell receptor Vbeta6 and Vbeta8 in arthritic joints. *Ann. Rheum. Dis.* 62, 983–990. doi: 10.1136/ard.62.10.983

Ciccia, F., Guggino, G., Rizzo, A., Manzo, A., Vitolo, B., La Mannia, M. P., et al. (2015). Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. *Rheumatol. (Oxford)* 54, 2264–2272. doi: 10.1093/rheumatology/kev225

Croft, E. H., Tailford, L. E., Le Gall, G., Fons, M., Henniats, B., and Juge, N. (2013). Utilisation of mucin glycans by the human gut symbiont Ruminococcus torvus is strain-dependent. *PloS One* 8, e76341. doi: 10.1371/journal.pone.0076341

Dantas, A. T., Marques, C. D., da Rocha Junior, L. F., Cavalcanti, M. B., Goncalves, S. M., Cardoso, P. R., et al. (2015). Increased Serum Interleukin-9 levels in rheumatoid arthritis and systemic lupus erythematosus: pathogenic role or just an epiphenomenon? *Dis. Markers* 2015, 519638. doi: 10.1155/2015/519638

Deshoe, R. B., Babu, R. J., and Srinivas, N. R. (2018). Reappraisal and perspectives of clinical drug-drug interaction potential of alpha-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. *Xenobiotica* 48, 89–108. doi: 10.1080/00498252.2016.1275063

DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., et al. (2006). Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. *Appl. Environ. Microbiol.* 72, 5069–5072. doi: 10.1128/AEM.03006-05

Dixon, P. (2003). VEGAN, a package of R functions for community ecology. *J. Veg. Sci.* 14, 927–930. doi: 10.1655/1164-1103.2003.020228.x

Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., et al. (2008). IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann. Rheum. Dis.* 67, 1516–1523. doi: 10.1136/ard.2008.092932

FUNDING
This project was funded by Portland VA Research Foundation and Arthritis and Rheumatic Disease Research Foundation of Oregon Health & Science University.

ACKNOWLEDGEMENTS
C-QC was supported by Rheumatology Research Foundation Innovative and Pilot grants and VA Merit Review grant (BX002858). LZ was supported by a scholarship of China Scholarship Council. QX was supported by a Guangzhou University of Chinese Medicine Scholarship. Part of the work was presented as a poster in the Annual Meeting of American College of Rheumatology, 2017 and the abstract was published in Arthritis & Rheumatology, 2017, 69 (suppl. 10). Authors have the permission to reuse these materials.
Lozupone, C., and Knight, R. (2005). UniFrac: a new phylogenetic method for comparing microbial communities. *Appl. Environ. Microbiol.* 71, 1228–1231. doi: 10.1128/AEM.71.4.1228-1231.2005

Scheppach, W., Fabian, C., Sachs, M., and Kasper, H. (1988). The effect of starch malabsorption on fecal short-chain fatty acid excretion in man. * scand. J. Gastroenterol.* 23, 755–759. doi: 10.3109/0036552809093945

Scher, J. U., and Abramson, S. B. (2011). The microbiome and rheumatoid arthritis. *Nat. Rev. Rheumatol.* 7, 569–578. doi: 10.1038/nrrheum.2011.121

Scher, J. U. (2016). The microbiome in celiac disease: beyond diet-genetic interactions. *Clin. Clin. Med.* 63, 228–230. doi: 10.3949/cjcm.83a.15123

Segain, J. P., Raingard de la Bletiere, D., Bouruelle, A., Leray, V., Gervois, N., Rosales, C., et al. (2000). Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn’s disease. *Gut* 47, 397–403. doi: 10.1136/gut.47.3.397

Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., et al. (2011). Metagenomic biomarker discovery and explanation. *Genome Biol.* 12, R60. doi: 10.1186/gb-2011-12-6-60

Sels, J.-P.É., Huijberts, M. S. P., and Wolfenbuttel, B. H. R. (1999). Miglitol, a new α-glucosidase inhibitor. *Expert Opin. Pharmacother.* 1, 149–156. doi: 10.1517/14656566.1.1.149

Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlody, Y. M., et al. (2013). The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* 341, 569–573. doi: 10.1126/science.1241165

Smith, B. J., Miller, R. A., Ericsson, A. C., Harrison, D. C., Strong, R., and Schmidt, T. M. (2019). Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice. *BMC Microbiol.* 19, 130. doi: 10.1186/s12866-019-1494-7

Su, B., Liu, H., Li, J., Sunli, Y., Liu, B., Liu, D., et al. (2015). Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. *J. Diabetes* 7, 729–739. doi: 10.1111/1753-0407.12232

Takatori, H., Kawashima, H., Matsuji, A., Meguro, K., Tanaka, S., Iwamoto, T., et al. (2015). Helios enhances treg cell function in cooperation with Foxp3. *Arthritis Rheumatol.* 67, 1491–1502. doi: 10.1002/art.39091

Tims, S., Demom, C., Jonkers, D. M., Viletinck, R., Saris, W. H., Kleerebezem, M., et al. (2013). Microbiota conservation and BMI signatures in adult monozygotic twins. *ISME J.* 7, 707–717. doi: 10.1038/ismej.2012.146

van den Berg, W. B., and Moosec, P. (2009). IL-17 as a future therapeutic target for rheumatoid arthritis. *Nat. Rev. Rheumatol.* 5, 545–553. doi: 10.1038/ nrrheum.2009.179

Walters, W. A., Xu, Z., and Knight, R. (2014). Meta-analyses of human gut microbes associated with obesity and IBD. *FEBS Lett.* 588, 4223–4233. doi: 10.1016/j.febslet.2014.09.039

Williams, R. O., Feldmam, M., and Maini, R. N. (1992). Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. *Proc. Natl. Acad. Sci. U. S. A.* 89, 9784–9788. doi: 10.1073/pnas.89.20.9784

Xavier, R. J., and Podolsky, D. K. (2007). Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 448, 427–434. doi: 10.1038/nature06005

Zabransky, D. J., Nirschl, C. J., Durham, N. M., Park, B. V., Ceccato, C. M., Bruno, T. C., et al. (2012). Phenotypic and functional properties of Helios+ regulatory T cells. *PLoS One* 7, e34547. doi: 10.1371/journal.pone.0034547

Zhang, X., Zhang, D., Jia, H., Feng, Q., Wang, D., Liang, D., et al. (2015). The oral microbiota-derived short-chain fatty acids, T cells, and inflammation. *Immunol. Netw.* 14, 277–288. doi: 10.4110/in.2014.14.6.277

Zhang et al. Acarbose Ameliorates Arthritis

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.